## genomics -online.com





## Human AGAP9 CRISPR gRNA + Cas9 in Lenti Particles

Overview	
Quantity:	300 μL
Gene:	AGAP9
Species:	Human
Insert:	gRNA + Cas9
Vector:	Lentiviral Vector
Application:	Genome Editing with Engineered Nucleases (GEEN), Protein Expression (PExp)
Product Details	
Purpose:	Individual gRNA against AGAP9 in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA
	and Cas9 in a single vector)
Vector Backbone:	pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro
Promoter:	U6 Promoter, SFFV Promoter
Selectable Marker:	Puromycin
Bacterial Resistance:	Ampicillin
Expression Type:	Stable, Transient
Sequence:	Sequence available upon placing order
Specificity:	GRNAs are designed for use with Cas9 Nuclease only.
	Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority
	of cells, except ES cells or iPS cells.
Sequencing Primer:	U6 Forward Primer: 5'TACGTCCAAGGTCGGGCAGGAAGA3'
Components:	Lentiviral particles with an individual gRNA (300 µL) for a specific sequence of AGAP9

## **Target Details**

Gene:	AGAP9
Alternative Name:	AGAP9 (AGAP9 Products)
NCBI Accession:	XM_001716810

Application Details		
Application Notes:	Recommended for quality control: Restriction Enzyme Digest and Sequencing	
Restrictions:	For Research Use only	
Handling		
Format:	Viral Particles	
Storage:	-80 °C	
Expiry Date:	12 months	
Publications		
Product cited in:	Johnson Drugan Millor Evans: "39" in: Val 1363 Jaqua Nuglais saids research on 29.30 (	

Product cited in: Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, (
1991)